```
=> s 475108-18-0
L1             1 475108-18-0
                 (475108-18-0/RN)

=> fil caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.44       1.11

FILE 'CAPLUS' ENTERED AT 09:46:05 ON 29 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Jun 2006  VOL 145 ISS 1
FILE LAST UPDATED: 28 Jun 2006  (20060628/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l1
L2             4 L1

=> d bib abs 1-4

L2   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2006:513385  CAPLUS
TI   Binary antitumor compositions comprising platinum(IV) derivatives with
     other chemotherapeutic agents including monoclonal antibody specific for
     insulin-like growth factor receptor 1
IN   Zong, Chen; Kirschmeier, Paul; Medeiros, Paul T.
PA   Schering Corporation, USA
SO   PCT Int. Appl., 100 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   WO 2006057998        A1    20060601    WO 2005-US42301         20051105
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
```

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-630581P P 20041124

AB The present invention provides combination compns. comprising Pt-based compds., including satraplatin, along with another chemotherapeutic agent such as temozolomide or lonafarnib. The combinations are useful for the prevention or treatment of cancer. Method of using the combinations to treat or prevent cancer are also provided.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:589418 CAPLUS

DN 141:117198

TI Therapeutic agent for wet age-related macular degeneration

IN Matsuno, Kiyoshi; Koyama, Shinji

PA Santen Pharmaceutical Co., Ltd., Japan; Kirin Beer Kabushiki Kaisha

SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004060373	A1	20040722	WO 2003-JP16854	20031226
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003292838	A1	20040729	AU 2003-292838	20031226
	JP 2004217649	A2	20040805	JP 2003-431849	20031226
PRAI	JP 2002-379857	A	20021227		
	WO 2003-JP16854	W	20031226		

GI



I

AB A therapeutic agent for wet age-related macular degeneration which contains as an active ingredient an N-quinolyloxyphenyl-N'-isoxazolylurea derivative represented by the general formula (I; wherein R1 and R2 each is C1-6 alkoxy; R3 is halogeno; R4 and R5 each is hydrogen, halogeno, etc.; and R6 and R7 each is hydrogen, halogeno, C1-4 alkyl, etc.). The compound has excellent choroidal angiogenesis inhibitory activity and is useful in treatments for wet age-related macular degeneration.

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:354935 CAPLUS
DN 140:363009
TI N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea salt crystals
IN Matsunaga, Naoki; Yoshida, Satoshi; Yoshino, Ayako; Nakajima, Tatsuo
PA Kirin Beer Kabushiki Kaisha, Japan
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004035572	A1	20040429	WO 2003-JP13439	20031021
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003301430	A1	20040504	AU 2003-301430	20031021
	EP 1559715	A1	20050803	EP 2003-756734	20031021
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 3763414	B2	20060405	JP 2004-544999	20031021
	US 2006052415	A1	20060309	US 2005-532104	20050421
PRAI	JP 2002-306101	A	20021021		
	WO 2003-JP13439	W	20031021		

AB This invention provides crystals of pharmaceutically acceptable salts of N-[2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea. The salt crystals are used in treating a disease selected from the group consisting of tumor, diabetic retinopathy, rheumatoid arthritis, psoriasis, atheroma arteriosclerosis, Kaposi's sarcoma and exudative age-related macular degeneration. The salt crystals have properties appropriate for prepns. for oral administration.
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:849617 CAPLUS
DN 137:370101
TI Preparation of quinoline derivatives having azolyl group and quinazoline derivatives as antitumor agents
IN Kubo, Kazuo; Sakai, Teruyuki; Nagao, Rika; Fujiwara, Yasunari; Isoe, Toshiyuki; Hasegawa, Kazumasa
PA Kirin Beer Kabushiki Kaisha, Japan
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002088110	A1	20021107	WO 2002-JP4279	20020426
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2445333	AA	20021107	CA 2002-2445333	20020426
JP 2003012668	A2	20030115	JP 2002-126869	20020426
JP 3602513	B2	20041215		
US 2003087907	A1	20030508	US 2002-132473	20020426
US 6821987	B2	20041123		
EP 1382604	A1	20040121	EP 2002-724651	20020426
EP 1382604	B1	20051228		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2002009216	A	20040706	BR 2002-9216	20020426
CN 1543459	A	20041103	CN 2002-812624	20020426
NZ 529046	A	20051028	NZ 2002-529046	20020426
EP 1652847	A1	20060503	EP 2005-28370	20020426

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR

ZA 2003007861	A	20041008	ZA 2003-7861	20031008
NO 2003004595	A	20031219	NO 2003-4595	20031014
JP 2004224800	A2	20040812	JP 2004-101164	20040330
US 2004229876	A1	20041118	US 2004-861446	20040607

PRAI JP 2001-132775 A 20010427
EP 2002-724651 A3 20020426
JP 2002-126869 A3 20020426
US 2002-132473 A3 20020426
WO 2002-JP4279 W 20020426

OS MARPAT 137:370101

GI



I

AB N-[(4-quinolinyl or 4-quinazolinyl)thio or -oxy]phenyl-N'-azolylurea derivs. represented by the formula (I) or pharmaceutically acceptable salts or solvates thereof [wherein X, Z = CH, N; Y = O, S; R1, R2, R3 = H, NO2, NH2, each (un)substituted C1-6 alkyl or alkoxy or C2-6 alkenyl or alkynyl; R4 = H; R5-R8 = H, halo, C1-4 alkyl, alkoxy, or alkylthio, CF3, NO2, NH2; R9, R10 = C1-6 alkyl, each (un)substituted C1-4 alkylcarbonyl or C1-6 alkyl; R11 = (un)substituted azolyl] are prepared These compds. are useful for the treatment of tumor, diabetic retinopathy, chronic articular rheumatism, psoriasis, atherosclerosis , and Kaposi's sarcoma. They are also used for inhibiting neovascularization of a target blood vessel by contacting them with vascular endothelial cells of the target blood vessel. Thus, 100 mg 2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]aniline was dissolved in 5 mL CHCl3 and 0.5 mL Et3N, treated with a solution of 100 mg triphosgene in CHCl3, and stirred at room

temperature for 15 min, followed by adding 49 mg 2-aminothiazole, and the resulting mixture was stirred at room temperature overnight to give 31 mg N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N;-(1,3-thiazol-2-yl)urea (II). II at 20 mg/kg/day for 9 days inhibited the growth of human lung cancer transplanted in nude mice by 92.0%. The compds. I in vitro showed IC50 of 0.001-0.0697 μM for inhibiting the phosphorylation of the intracellular domain of human vascular endothelial cell growth factor (VEGF) receptor KDR (kinase insert domain-containing receptor) in IH3T3 cell expressing human KDR.

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.42	12.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

FILE 'STNGUIDE' ENTERED AT 09:46:39 ON 29 JUN 2006

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 23, 2006 (20060623/UP).

=>

```
=> s us6821987/pn
L5            1 US6821987/PN

=> analyze l5
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
L6          ANALYZE L5 1 RN :     109 TERMS

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    14.86      41.52

FILE 'REGISTRY' ENTERED AT 10:45:49 ON 29 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 JUN 2006  HIGHEST RN 889935-59-5
DICTIONARY FILE UPDATES:  28 JUN 2006  HIGHEST RN 889935-59-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s l6
L7          109 L6

=> s l7 and (quinol?(l)isoxaz?)
          793870 QUINOL?
          199220 ISOXAZ?
            4281 QUINOL?(L)ISOXAZ?
L8             9 L7 AND (QUINOL?(L)ISOXAZ?)

=> d 1-9

L8   ANSWER 1 OF 9  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   475108-23-7  REGISTRY
```

ED Entered STN: 04 Dec 2002
CN Urea, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-fluorophenyl]-N'-(5-methyl-3-isoxazolyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-[4-[(6,7-Dimethoxy-4-quinolyl)oxy]-2-fluorophenyl]-N'-(5-methyl-3-isoxazolyl)urea
FS 3D CONCORD
MF C22 H19 F N4 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 475108-22-6 REGISTRY
ED Entered STN: 04 Dec 2002
CN Urea, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-3-fluorophenyl]-N'-(5-methyl-3-isoxazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-[4-[(6,7-Dimethoxy-4-quinolyl)oxy]-3-fluorophenyl]-N'-(5-methyl-3-isoxazolyl)urea hydrochloride
MF C22 H19 F N4 O5 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CRN (789485-06-9)

PAGE 1-A



PAGE 2-A

● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 475108-21-5 REGISTRY
ED Entered STN: 04 Dec 2002
CN Urea, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-3-fluorophenyl]-N'-(3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-[4-[(6,7-Dimethoxy-4-quinolyl)oxy]-3-fluorophenyl]-N'-(3-methyl-5-isoxazolyl)urea
FS 3D CONCORD
MF C22 H19 F N4 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 475108-20-4 REGISTRY
ED Entered STN: 04 Dec 2002
CN Urea, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-fluorophenyl]-N'-(3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-[4-[(6,7-Dimethoxy-4-quinolyl)oxy]-2-fluorophenyl]-N'-(3-methyl-5-isoxazolyl)urea
FS 3D CONCORD
MF C22 H19 F N4 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 475108-19-1 REGISTRY
ED Entered STN: 04 Dec 2002
CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(3-methyl-5-isoxazolyl)urea
FS 3D CONCORD
MF C22 H19 Cl N4 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 475108-18-0 REGISTRY
ED Entered STN: 04 Dec 2002
CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea
FS 3D CONCORD
MF C22 H19 Cl N4 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 475108-17-9 REGISTRY
ED Entered STN: 04 Dec 2002
CN Urea, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-3-fluorophenyl]-N'-3-isoxazolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-[4-[(6,7-Dimethoxy-4-quinolyl)oxy]-3-fluorophenyl]-N'-(3-isoxazolyl)urea
FS 3D CONCORD
MF C21 H17 F N4 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 475108-16-8 REGISTRY
ED Entered STN: 04 Dec 2002
CN Urea, N-[3-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-[3-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(3-methyl-5-isoxazolyl)urea
FS 3D CONCORD
MF C22 H19 Cl N4 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 475108-15-7 REGISTRY
ED Entered STN: 04 Dec 2002
CN Urea, N-[3-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-3-isoxazolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-[3-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(3-isoxazolyl)urea
FS 3D CONCORD
MF C21 H17 Cl N4 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL